Welcome to our dedicated page for Apyx Medical SEC filings (Ticker: APYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Apyx Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Apyx Medical's regulatory disclosures and financial reporting.
On July 24, 2026, Apyx Medical Corporation reported that its Board of Directors reconstituted the membership and chairs of its standing committees.
Following his appointment as Executive Chairman effective June 11, 2026, Stavros Vizirgianakis will not serve on any Board committee. The Board determined that Mr. Waldman, Ms. Baylor-Henry, and Ms. Levine are independent under applicable Nasdaq Global Select Market and SEC rules and that Mr. Waldman qualifies as an audit committee financial expert under SEC regulations.
Royce & Associates reports amended beneficial ownership of Apyx Medical Corporation common stock. The firm beneficially owns 3,274,064 shares, representing 7.81% of the class as of June 30, 2026. It has sole power to vote and dispose of all reported shares and no shared voting or dispositive power.
The shares are held in investment management accounts of clients of Royce & Associates, LP, an indirect majority-owned subsidiary of Franklin Resources, Inc. Royce & Associates states the holdings are maintained in the ordinary course of business, disclaims pecuniary interest and beneficial ownership beyond Rule 13d-3, and indicates the position is not held to change or influence control of Apyx Medical Corporation.
Apyx Medical Corp director Lawrence Waldman reported a routine stock option exercise with tax withholding. On June 30, 2026, a Spousal Lifetime Access Trust associated with him exercised 12,000 stock options at an exercise price of $1.88 per share. Under the net exercise terms, 5,024 shares that would have been issued were instead withheld by the company at a value of $4.49 per share to cover the aggregate exercise price, and 6,976 net shares were issued. Following these transactions, the filing shows 37,563 common shares held directly and 12,314 shares held indirectly through the trust, while the exercised option grant was reduced to zero. The footnotes state the trust is a Spousal Lifetime Access Trust and that Waldman disclaims beneficial ownership of its holdings except for any pecuniary interest.
Apyx Medical Corporation is soliciting proxies for its 2026 Annual Meeting of Stockholders on August 6, 2026, where holders will vote to elect five directors, ratify RSM US LLP as auditor, approve a non-binding say-on-pay resolution, and approve the 2026 Share Incentive Plan.
Stockholders of record at the close of business on June 15, 2026, when 41,912,040 common shares were outstanding, are entitled to vote. The proxy statement also reviews 2025 developments, including FDA 510(k) clearance and commercial launch of the AYON body contouring system, Renuvion’s launch in China, and a November 2025 equity offering of 2,762,431 shares at $3.62 for approximately $9.1 million in net proceeds.
The filing details executive and director compensation, with CEO Charles D. Goodwin’s 2025 total compensation of $1,233,863, an at-risk bonus framework tied to performance, significant stock option grants, and an executive compensation clawback policy. It also highlights governance structures such as a majority-independent board, four standing committees, a lead independent director, a code of ethics, and an insider trading policy.
Apyx Medical Corp Chief Operating Officer Shawn David Roman reported a net stock option exercise through The Roman Family Revocable Trust. On June 15, 2026, he exercised 15,000 stock options at an exercise price of $3.23 per share.
To cover the aggregate exercise price, 10,533 shares of common stock otherwise issuable were withheld by the issuer at a value of $4.60 per share as a tax and exercise-price payment. As a result, 4,467 net shares of common stock were issued to the trust. Following the tax-withholding disposition, the trust held 16,467 shares of Apyx Medical common stock indirectly for the reporting person.
Apyx Medical Corporation has appointed Board Chairman Stavros Vizirgianakis as Executive Chairman under a new letter agreement dated June 11, 2026. In this role, he will provide strategic leadership, governance oversight, support for corporate initiatives, investor engagement, and advice on capital markets and corporate development.
In connection with this appointment and in recognition of his service, the Board granted Mr. Vizirgianakis 450,000 restricted stock units under the 2023 Share Incentive Plan. Of these, 150,000 RSUs vest immediately on June 11, 2026, with two additional tranches of 150,000 RSUs each vesting monthly over 12-month periods starting on the first and second anniversaries of the grant date. He will not be an officer or "executive officer" of the company.
Apyx Medical Corp director Wendy Lauren Levine received a grant of stock options as part of her compensation. She was awarded options to purchase 50,000 shares of Apyx common stock at an exercise price of $4.65 per share, expiring on June 11, 2036. According to the disclosure, the option grant vests ratably over a twelve-month period and becomes fully vested and exercisable on the first anniversary of the grant date. After this award, she holds 50,000 stock options directly.
Vizirgianakis Stavros G. reported acquisition or exercise transactions in this Form 4 filing.
Apyx Medical Corp director Stavros G. Vizirgianakis received a grant of 450,000 restricted stock units (RSUs). The award was granted at no cash cost per unit and is compensation rather than an open-market purchase.
According to the vesting schedule, 150,000 RSUs vest on June 11, 2026, 150,000 begin vesting on the first anniversary of that date and vest ratably over the following twelve months, and the remaining 150,000 follow the same ratable schedule starting on the second anniversary. After this grant, Vizirgianakis directly holds 2,196,191 shares or share-equivalents reported in this filing.
Apyx Medical Corp disclosed that Chief Executive Officer Charles D. Goodwin II received a grant of stock options for 213,948 shares of common stock. The options have an exercise price of $4.65 per share, vest ratably over 36 months, and become fully exercisable on the third anniversary of the grant date.
Apyx Medical Corp reported that Chief Operating Officer Shawn David Roman received a grant of stock options on Common Stock. The award covers 88,044 underlying shares with an exercise price of $4.65 per share and expires on June 11, 2036.
The options were granted as compensation and will vest ratably over 36 months, becoming fully vested and exercisable on the third anniversary of the grant date. Following this award, Roman holds 88,044 stock options directly, with no open-market share purchases or sales disclosed in this filing.